Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01423604 · ClinicalTrials.gov registry record · Phase 2
Study of Ruxolitinib in Pancreatic Cancer Patients
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT01423604 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 136 participants.
The verdict
NCT01423604, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study was to determine whether ruxolitinib added to capecitabine is effective in improving the overall survival of patients with metastatic pancreatic cancer.
Interventions
- DRUG Placebo
- DRUG Capecitabine
- DRUG Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2011-07 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01423604
The ClinicalTrials.gov registry entry for NCT01423604 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01423604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01423604 about?
NCT01423604 is a clinical study titled "Study of Ruxolitinib in Pancreatic Cancer Patients". The purpose of this study was to determine whether ruxolitinib added to capecitabine is effective in improving the overall survival of patients with metastatic pancreatic cancer.
What is the current status of trial NCT01423604?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2011-07. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01423604?
The interventions under investigation include: Placebo (DRUG), Capecitabine (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT01423604?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.